Clinical trial NCT07025187: the Effect of Integrated Neuomuscular Inhibition Technique on Adult Females With Cervicogenic Headache
Official title: the Effect of Integrated Neuomuscular Inhibition Technique on Adult Females With Cervicogenic Headache
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Cervicogenic Headache
Lead sponsor: Kafrelsheikh University
Sponsor class: OTHER
First posted: 2025-06-17
Enrollment: 40
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the current study is investigating the effect of integrated neuromuscular inhibition technique on adult females with cervicogenic headache.

Methods: Forty females with cervicogenic headache will be recruited. Patients will be randomly assigned into two groups, group A and group B . Patients in both groups will receive a traditional medical treatment, but group (B) will receive additional integrated neuromuscular inhibition technique.

Detailed description: Measurements will be taken for all participants before the start of treatment program then after the end of 4 weeks treatment program, then after another 4 weeks of follow up.all patients will be evaluated for headache pain intensity, cervicogenic headache frequency, cervicogenic headache duration, cervical range of motion in all directions, the isometric endurance capacity of sternocledomastoid and anterior scalene, kinesiophobia, neck disability, and headache impact test-6.

All patients will receive a traditional medical program by an experienced neurologist in the form of Muscle relaxants tizanidine ,4 mg to 32 mg, Three times a day.

Patients in experimental group (B) will receive the same program as control group (A) plus the INIT for upper trapezius and suboccipital muscles. The INIT program will be administrated three times a week for one month.

Eligibility criteria: Inclusion Criteria:

* A diagnosis of CGH will be made by an experienced neurologist as per the International Classification of Headache Disorders 3rd edition (ICHD-3) , but not including occipital nerve blockage . Additional inclusion criteria will include female patients aged\> 18 years and\<60 years; headache intensity ≥ 3 on eleven-point numerical rating scale at enrolment; at least three-month history of headache with a mean frequency of \> 1/week; hypomobility of the upper cervical spine (C0 to C3) on manual examination; and reproduction of the headache on palpation of the upper cervical spine (C0 to C3).In addition, patients should exhibit active trigger points within the suboccipital, and upper trapezius muscles, ipsilaterally over the symptomatic side reproducing their headache symptoms .

Exclusion Criteria:

* Patients will be excluded if they have any of the following: cervical radiculopathy, history of neck, shoulder trauma or surgery, history of intervention for head or neck pain within the previous 3 months,or a diagnosis of other types of headaches using the criteria of ICHD-3.

Primary outcomes:
measure: headache frequency
timeFrame: Baseline, 4 weeks and 8 weeks
measure: headache duration
timeFrame: Baseline, 4 weeks and 8 weeks .
measure: headache pain intensity
timeFrame: Baseline, 4 weeks and 8 weeks .
measure: cervical ROM in all directions
timeFrame: Baseline, 4 weeks and 8 weeks .
Secondary outcomes:
measure: kinesiophobia
timeFrame: Baseline, 4 weeks and 8 weeks .
measure: the endurance of neck flexors
timeFrame: Baseline, 4 weeks and 8 weeks .
measure: the impact of headaches on patients' lives
timeFrame: Baseline, 4 weeks and 8 weeks .
measure: neck disability
timeFrame: Baseline, 4 weeks and 8 weeks .
Other outcomes:
Locations:
Study officials:
References: